Modulatory effects of perindopril on cisplatin-induced nephrotoxicity in mice: Implication of inflammatory cytokines and caspase-3 mediated apoptosis
References
- 1. S. Dasari and P. B. Tchounwou, Cisplatin in cancer therapy: molecular mechanisms of action, Eur. J. Pharmacol.740 (2014) 364–378; https://doi.org/10.1016/j.ejphar.2014.07.02510.1016/j.ejphar.2014.07.025
- 2. I. Arany and R. L. Safirstein, Cisplatin nephrotoxicity, Semin. Nephrol.23 (2003) 460–464; https://doi.org/10.1016/S0270-9295(03)00089-510.1016/S0270-9295(03)00089-5
- 3. A. Shiraishi, K. Sakumi and M. Sekiguchi, Increased susceptibility to chemotherapeutic alkylating agents of mice deficient in DNA repair methyltransferase, Carcinogenesis21 (2000) 1879–1883; https://doi.org/10.1093/carcin/21.10.187910.1093/carcin/21.10.187911023546
- 4. N. Pabla and Z. Dong, Cisplatin nephrotoxicity: mechanisms and renoprotective strategies, Kidney Int.73 (2008) 994–1007; https://doi.org/10.1038/sj.ki.500278610.1038/sj.ki.500278618272962
- 5. P. D. Sanchez-Gonzalez, F. J. Lopez-Hernandez, J. M. Lopez-Novoa and A. I. Morales, An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity, Crit. Rev. Toxicol.41 (2011) 803–821; https://doi.org/10.3109/10408444.2011.60266210.3109/10408444.2011.60266221838551
- 6. G. Daugaard, U. Abildgaard, N. H. Holstein-Rathlou, I. Bruunshuus, D. Bucher and P. P. Leyssac, Renal tubular function in patients treated with high-dose cisplatin, Clin. Pharmacol. Ther.44 (1988) 164–172; https://doi.org/10.1038/clpt.1988.13210.1038/clpt.1988.1322840230
- 7. A. M. Abdelrahman, Y. Al Suleimani, A. Shalaby, M. Ashique, P. Manoj, A. Nemmar and B. H. Ali, Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on cisplatin-induced nephrotoxicity in mice, Naunyn. Schmiedebergs Arch. Pharmacol. (2018); https://doi.org/10.1007/s00210-018-1564-710.1007/s00210-018-1564-730206656
- 8. G. J. Dugbartey, L. J. Peppone and I. A. de Graaf, An integrative view of cisplatin-induced renal and cardiac toxicities: Molecular mechanisms, current treatment challenges and potential protective measures, Toxicology371 (2016) 58–66; https://doi.org/10.1016/j.tox.2016.10.00110.1016/j.tox.2016.10.001558659427717837
- 9. C. N. Sharp and L. J. Siskind, Developing better mouse models to study cisplatin-induced kidney injury, Am. J. Physiol. Renal Physiol.313 (2017) F835-f841; https://doi.org/10.1152/ajprenal.00285.201710.1152/ajprenal.00285.2017566858228724610
- 10. M. Hurst and B. Jarvis, Perindopril: an updated review of its use in hypertension, Drugs61 (2001) 867–896; https://doi.org/10.2165/00003495-200161060-0002010.2165/00003495-200161060-0002011398915
- 11. P. A. Todd and A. Fitton, Perindopril. A review of its pharmacological properties and therapeutic use in cardiovascular disorders, Drugs42 (1991) 90–114; https://doi.org/10.2165/00003495-199142010-0000610.2165/00003495-199142010-000061718688
- 12. E. M. de Cavanagh, F. Inserra and L. Ferder, Angiotensin II blockade: a strategy to slow ageing by protecting mitochondria?, Cardiovasc Res.89 (2011) 31–40; https://doi.org/10.1093/cvr/cvq28510.1093/cvr/cvq28520819950
- 13. E. A. M. El-Shoura, B. A. S. Messiha, S. M. Z. Sharkawi and R. A. M. Hemeida, Perindopril ameliorates lipopolysaccharide-induced brain injury through modulation of angiotensin-II/angiotensin-1-7 and related signaling pathways, Eur. J. Pharmacol.834 (2018) 305–317; https://doi.org/10.1016/j.ejphar.2018.07.04610.1016/j.ejphar.2018.07.04630059682
- 14. N. E. Mohammed, B. A. Messiha and A. A. Abo-Saif, Effect of amlodipine, lisinopril and allopurinol on acetaminophen-induced hepatotoxicity in rats, Saudi Pharm. J.24 (2016) 635–644; https://doi.org/10.1016/j.jsps.2015.04.00410.1016/j.jsps.2015.04.004509442927829805
- 15. M. M. Abdel-Fattah, A. A. Salama, B. A. Shehata and I. E. Ismaiel, The potential effect of the angiotensin II receptor blocker telmisartan in regulating OVA-induced airway remodeling in experimental rats, Pharmacol. Rep.67 (2015) 943–951; https://doi.org/10.1016/j.pharep.2015.02.01010.1016/j.pharep.2015.02.01026398389
- 16. M. G. Fahmy Wahba, B. A. Shehata Messiha and A. A. Abo-Saif, Ramipril and haloperidol as promising approaches in managing rheumatoid arthritis in rats, Eur. J. Pharmacol.765 (2015) 307–15; https://doi.org/10.1016/j.ejphar.2015.08.02610.1016/j.ejphar.2015.08.02626302059
- 17. F. Barutta, S. Bellini, R. Mastrocola, R. Gambino, F. Piscitelli, V. di Marzo, B. Corbetta, V. K. Vemuri, A. Makriyannis, L. Annaratone, L. Annaratone, G. Bruno and G. Gruden, Reversal of albuminuria by combined AM6545 and perindopril therapy in experimental diabetic nephropathy, Br. J. Pharmacol.175 (2018) 4371–4385; https://doi.org/10.1111/bph.1449510.1111/bph.14495624013030184259
- 18. X. M. Gao, A. Tsai, A. Al-Sharea, Y. Su, S. Moore, L. P. Han, H. Kiriazis, A. M. Dart, A. J. Murphy and X. J. Du, Inhibition of the renin-angiotensin system post myocardial infarction prevents inflammation-associated acute cardiac rupture, Cardiovasc. Drugs Ther.31 (2017) 145–156; https://doi.org/10.1007/s10557-017-6717-210.1007/s10557-017-6717-228204966
- 19. K. K. Filipski, R. H. Mathijssen, T. S. Mikkelsen, A. H. Schinkel and A. Sparreboom, Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity, Clin. Pharmacol. Ther.86 (2009) 396–402; https://doi.org/10.1038/clpt.2009.13910.1038/clpt.2009.139274686619625999
- 20. F. A. Suliman, D. M. Khodeer, A. Ibrahiem, E. T. Mehanna, M. K. El-Kherbetawy, H. M. F. Mohammad, S. A. Zaitone and Y. M. Moustafa, Renoprotective effect of the isoflavonoid biochanin A against cisplatin induced acute kidney injury in mice: Effect on inflammatory burden and p53 apoptosis, Int. Immunopharmacol.61 (2018) 8–19; https://doi.org/10.1016/j.intimp.2018.05.01010.1016/j.intimp.2018.05.01029793166
- 21. A. S. Shalkami, M. I. A. Hassan and A. A. Abd El-Ghany, Perindopril regulates the inflammatory mediators, NF-kappaB/TNF-alpha/IL-6, and apoptosis in cisplatin-induced renal dysfunction, Naunyn. Schmiedebergs Arch. Pharmacol.391 (2018) 1247–1255; https://doi.org/10.1007/s00210-018-1550-010.1007/s00210-018-1550-030066022
- 22. I. Rubera, C. Duranton, N. Melis, M. Cougnon, B. Mograbi and M. Tauc, Role of CFTR in oxidative stress and suicidal death of renal cells during cisplatin-induced nephrotoxicity, Cell Death Dis.4 (2013) e817; https://doi.org/10.1038/cddis.2013.35510.1038/cddis.2013.355382466524091660
- 23. H. Soni, D. Kaminski, R. Gangaraju and A. Adebiyi, Cisplatin-induced oxidative stress stimulates renal Fas ligand shedding, Ren. Fail.40 (2018) 314–322; https://doi.org/10.1080/0886022x.2018.145693810.1080/0886022X.2018.1456938601430329619879
- 24. R. Goel, S. A. Bhat, K. Hanif, C. Nath and R. Shukla, Perindopril attenuates lipopolysaccharideinduced amyloidogenesis and memory impairment by suppression of oxidative stress and RAGE activation, ACS Chem. Neurosci.7 (2016) 206–217; https://doi.org/10.1021/acschemneuro.5b0027410.1021/acschemneuro.5b0027426689453
- 25. A. Dandekar, R. Mendez and K. Zhang, Cross talk between ER stress, oxidative stress, and inflammation in health and disease, Methods Mol. Biol.1292 (2015) 205–14; https://doi.org/10.1007/978-1-4939-2522-3_1510.1007/978-1-4939-2522-3_1525804758
- 26. F. Sesti, O. E. Tsitsilonis, A. Kotsinas and I. P. Trougakos, Oxidative stress-mediated biomolecular damage and inflammation in tumorigenesis, In Vivo26 (2012) 395–402.
- 27. K. Hasegawa, S. Wakino, K. Yoshioka, S. Tatematsu, Y. Hara, H. Minakuchi, N. Washida, H. Tokuyama, K. Hayashi and H. Itoh, Sirt1 protects against oxidative stress-induced renal tubular cell apoptosis by the bidirectional regulation of catalase expression, Biochem. Biophys. Res. Commun.372 (2008) 51–56; https://doi.org/10.1016/j.bbrc.2008.04.17610.1016/j.bbrc.2008.04.17618485895
- 28. M. H. Hassan, S. A. Bahashawan, T. M. Abdelghany, G. M. Abd-Allah and M. M. Ghobara, Crocin abrogates carbon tetrachloride-induced renal toxicity in rats via modulation of metabolizing enzymes and diminution of oxidative stress, apoptosis, and inflammatory cytokines, J. Biochem. Mol. Toxicol.29 (2015) 330–339; https://doi.org/10.1002/jbt.2170210.1002/jbt.2170225899501
- 29. J. Y. Kim, J. H. Park, K. Kim, J. Jo, J. Leem and K. K. Park, Pharmacological inhibition of caspase-1 ameliorates cisplatin-induced nephrotoxicity through suppression of apoptosis, oxidative stress, and inflammation in mice, Mediators Inflamm.2018(2018) 6571676; https://doi.org/10.1155/2018/657167610.1155/2018/6571676632343830670928
- 30. J. L. Martindale and N. J. Holbrook, Cellular response to oxidative stress: signaling for suicide and survival, J. Cell Physiol.192 (2002) 1–15; https://doi.org/10.1002/jcp.1011910.1002/jcp.1011912115731
- 31. G. Nunez, M. A. Benedict, Y. Hu and N. Inohara, Caspases: the proteases of the apoptotic pathway, Oncogene17 (1998) 3237–3245; https://doi.org/10.1038/sj.onc.120258110.1038/sj.onc.12025819916986
- 32. E. A. Slee, M. T. Harte, R. M. Kluck, B. B. Wolf, C. A. Casiano, D. D. Newmeyer, H. G. Wang, J. C. Reed, D. W. Nicholson, E. S. Alnemri, D. R. Green and S. J. Martin, Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner, J. Cell Biol.144 (1999) 281–292; https://doi.org/10.1083/jcb.144.2.28110.1083/jcb.144.2.28121328959922454
Language: English
Page range: 515 - 525
Accepted on: Nov 18, 2019
Published on: May 13, 2020
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
Related subjects:
© 2020 Naif Aljuhani, Raed S. Ismail, Mohammed S. El-Awady, Memy H. Hassan, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.